Biotechnology company, Resverlogix Corp. in Calgary, Canada, is developing a first-in-class small-molecule oral drug, RVX-208, to clear plaque out of arteries, something that leading drugs in the $35 billion cholesterol market have so far failed to do.
Peripheral artery disease (PAD) is a collator for diseases caused by the obstruction of large peripheral arteries resulting from atherosclerosis or other inflammatory processes that can lead to acute or chronic ischemia.
In the past few years, scientists have discovered RNA involvement in more and more processes. Consequently, researchers need improved techniques for working with this molecule.
Call 2009 the Year of the Vaccine, or at least the Year of the Vaccine Shortage, as supplies of H1N1 influenza vaccine fail to keep pace with demand from governments around the world.
The ECIS (Electric Cell-substrate Impedance Sensing) Z and ECIS Z Theta instruments can be equipped with a flow option for studying the behavior of cells.
Fluxion Biosciences introduces the BioFlux 1000 Workstation—a cell analysis system that integrates the company’s well plate microfluidic technology with automated microscopy for high-throughput shear flow assays.
Flow cytometry was previously considered a major research tool for preclinical studies (albeit a slow one), but its use is expanding into other areas of drug development as the need to analyze complex cellular mixtures, as opposed to cell lines, increases.
Current technologies such as iPS cells and their use in the differentiation and manufacture of various mature, differentiated human cells have improved the accuracy of toxicity data, allowing drug developers to more closely predict drug response in humans.
As collections of compounds and biological samples expand, biotechnology and pharmaceutical companies seek more-efficient ways to keep track of these libraries, and that requires improved automation. Lessons learned from managing chemical samples can lead to better choices for biological ones.
Apogenix GmbH announced that the European Medicines Agency adopted a positive opinion on orphan medicinal product designation for the company’s lead candidate APG101 for the treatment of Glioblastoma multifome.
Alizé Pharma has developed an improved L-asparaginase product with increased potency, reduced immunogenicity, and longer duration of action.
Genentech, Inc. has submitted two supplemental Biologics License Applications to the U.S. Food and Drug Administration for Avastin for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer.
Pall Life Sciences introduces Mustang Q XT ion exchange chromatography capsules in a new re-usable format, offering flexibility and high performance for process chromatography.
Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.